LobbyingBiohaven lobbying by quarter
Biohaven BHVN's latest lobbying report covers Q2 2026, at $120K. Its first report covers Q1 2026; the issues it reports most are Health Issues and Medical/Disease Research/Clinical Labs.
BiohavenBHVN
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $200K
- Last 3 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q1 2026
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q1 2026 | $80K | 1 |
| Q2 2026 | $120K | 1 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$66.7K · 2 reports
- Medical research and clinical labs$66.7K · 2 reports
- Pharmacy$66.7K · 2 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- Food & Drug Administration (FDA)2 reports
- Health & Human Services, Dept of (HHS)2 reports
- White House Office2 reports
- Centers For Medicare and Medicaid Services (CMS)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| Checkmate Government Relations | $200K | 2 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| TIMOTHY LUCAS BLANCHAT | Chief of Staff, Congressman Richard Hudson; Deputy State Director, Senator Thom Tillis | Q2 2026 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/17for Q2 | Checkmate Government Relations | $120K |
| 04/19for Q1 | Checkmate Government Relations | $80K |
| 02/24for Q1 | Checkmate Government Relations | Under $5,000 |